Comparison · Melanocortin analog
Melanotan-2 vs PT-141
These compounds share a catalog class. That grouping makes their declared properties useful to compare, but does not establish experimental or clinical interchangeability.
For in vitro and laboratory research only. Not for human or veterinary use, diagnosis or treatment. These research materials have not been evaluated by COFEPRIS.
What distinguishes these compounds
PT-141 is structurally derived from Melanotan-2 by replacing the terminal amide group with a carboxylic acid. Both are cyclic heptapeptide analogues, but the terminal group is a chemical distinction that should remain visible in an identity comparison.
Melanotan-2 is described as having a nonselective melanocortin profile including MC1R, MC3R and MC4R. PT-141's entry reports a preference for MC4R and MC3R. Relative preference is not the same as absolute receptor exclusivity or equivalent biological response.
What they are
Melanotan-2: Melanotan-2 is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone, cyclized through a lactam bridge. In preclinical models, it binds to several melanocortin receptors, including MC1R, MC3R and MC4R, with a nonselective profile. It has been investigated in models of melanocortin signaling in rodent studies.
PT-141: PT-141 is a cyclic heptapeptide analog of alpha-MSH, structurally derived from Melanotan-2 by replacing the terminal amide group with a carboxylic acid. In research literature, it binds to melanocortin receptors with a reported preference for MC4R and MC3R. It has been studied in models of central melanocortin signaling in rodent studies.
Mechanisms described in the literature
Melanotan-2: Cyclization restricts the peptide's conformation and modifies its relative affinity for receptor subtypes. All of these are Gs protein-coupled receptors in cellular models.
PT-141: MC4R is a Gs protein-coupled receptor expressed in hypothalamic nuclei. Its activation modulates cyclic AMP production in cellular models.
Declared chemical identity, field by field
A dash means that the catalog does not declare that field for the compound. If neither entry declares a field, the row is omitted. A label purity specification of ≥ 99 % is not an analytical result; results must come from the certificate for the relevant batch.
| Field | Melanotan-2 | PT-141 |
|---|---|---|
| Chemical name | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Molecular formula | C50H69N15O9 | C50H68N14O10 |
| Molecular weight | 1024.2 Da | 1025.16 Da |
| CAS number | 121062-08-6 | 189691-06-3 |
| Form | Lyophilized powder | Lyophilized powder |
| Appearance | White to off-white solid | White to off-white solid |
| Solubility | Soluble in sterile water and bacteriostatic water | Soluble in sterile water and bacteriostatic water |
| Storage | −20 °C, protected from light | −20 °C, protected from light |
| Stability after reconstitution | Keep refrigerated at 2–8 °C and use within the period defined by the laboratory protocol | Keep refrigerated at 2–8 °C and use within the period defined by the laboratory protocol |
Laboratory handling: Melanotan-2
Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.
Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.
Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.
Laboratory handling: PT-141
Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.
Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.
Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.
Catalog presentations
Consult each product page for its current presentations, availability, batch documentation and price. This comparison does not freeze commercial information in the research text.
Complete research references
The compendium entries contain the extended definitions, research context and indexed bibliography for each compound. The comparison organizes declared information; it does not replace study-specific interpretation or batch identity evidence.
Sources
- Discovery and development of novel melanogenic drugs. Melanotan-I and -II — Pharm Biotechnol (1998); PMID 9760697; DOI 10.1007/0-306-47384-4_25
- Discovery and development of novel melanogenic drugs. Melanotan-I and -II — Pharm Biotechnol (1998); PMID 9760697; DOI 10.1007/0-306-47384-4_25
- Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization — Peptides (2006); PMID 16412534; DOI 10.1016/j.peptides.2005.01.029
- Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization — Peptides (2006); PMID 16412534; DOI 10.1016/j.peptides.2005.01.029
- Melanotan II User Experience: A Qualitative Study of Online Discussion Forums — Dermatology (2021); PMID 34464955; DOI 10.1159/000514492
- Melanotan II User Experience: A Qualitative Study of Online Discussion Forums — Dermatology (2021); PMID 34464955; DOI 10.1159/000514492
- Melanotan II: a possible cause of renal infarction: review of the literature and case report — CEN Case Rep (2020); PMID 31953620; DOI 10.1007/s13730-020-00447-z
- Melanotan II: a possible cause of renal infarction: review of the literature and case report — CEN Case Rep (2020); PMID 31953620; DOI 10.1007/s13730-020-00447-z
- Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. — J Med Chem (1989); PMID 2555512; DOI 10.1021/jm00132a010
- Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. — J Med Chem (1989); PMID 2555512; DOI 10.1021/jm00132a010
- A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotan-II. Plasma and brain tissue concentrations following administration in mice. — Rapid Commun Mass Spectrom (2007); PMID 17610239; DOI 10.1002/rcm.3106
- A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotan-II. Plasma and brain tissue concentrations following administration in mice. — Rapid Commun Mass Spectrom (2007); PMID 17610239; DOI 10.1002/rcm.3106
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. — Obstet Gynecol (2019); PMID 31599840; DOI 10.1097/AOG.0000000000003500
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. — Obstet Gynecol (2019); PMID 31599840; DOI 10.1097/AOG.0000000000003500
- Safety Profile of Bremelanotide Across the Clinical Development Program. — J Womens Health (Larchmt) (2022); PMID 35147466; DOI 10.1089/jwh.2021.0191
- Safety Profile of Bremelanotide Across the Clinical Development Program. — J Womens Health (Larchmt) (2022); PMID 35147466; DOI 10.1089/jwh.2021.0191
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. — J Sex Med (2006); PMID 16839319; DOI 10.1111/j.1743-6109.2006.00268.x
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. — J Sex Med (2006); PMID 16839319; DOI 10.1111/j.1743-6109.2006.00268.x
- Structural insights into ligand recognition and activation of the melanocortin-4 receptor — Cell Res (2021); PMID 34433901; DOI 10.1038/s41422-021-00552-3
- Structural insights into ligand recognition and activation of the melanocortin-4 receptor — Cell Res (2021); PMID 34433901; DOI 10.1038/s41422-021-00552-3
- Bremelanotide: an overview of preclinical CNS effects on female sexual function — J Sex Med (2007); PMID 17958619; DOI 10.1111/j.1743-6109.2007.00610.x
- Bremelanotide: an overview of preclinical CNS effects on female sexual function — J Sex Med (2007); PMID 17958619; DOI 10.1111/j.1743-6109.2007.00610.x
- The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women — CNS Spectr (2022); PMID 33455598; DOI 10.1017/S109285292100002X
- The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women — CNS Spectr (2022); PMID 33455598; DOI 10.1017/S109285292100002X
- Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. — J Pharm Biomed Anal (2020); PMID 32353679; DOI 10.1016/j.jpba.2020.113276
- Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. — J Pharm Biomed Anal (2020); PMID 32353679; DOI 10.1016/j.jpba.2020.113276
- PT-141: a melanocortin agonist for the treatment of sexual dysfunction. — Ann N Y Acad Sci (2003); PMID 12851303; DOI 10.1111/j.1749-6632.2003.tb03167.x
- PT-141: a melanocortin agonist for the treatment of sexual dysfunction. — Ann N Y Acad Sci (2003); PMID 12851303; DOI 10.1111/j.1749-6632.2003.tb03167.x